FIMECS
Fujisawa, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Japanese biotech developing targeted protein degradation drugs for undruggable oncology targets using its proprietary RaPPIDS™ platform.
Oncology
Technology Platform
RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) - a drug discovery platform for targeted protein degradation using diversity-oriented synthesis and proprietary E3 ligase binders.
Opportunities
Expansion into additional undruggable target classes beyond pseudokinases, leveraging RaPPIDS™ platform for new partnerships, and potential first-mover advantage in IRAK-M degradation for cancer immunotherapy.
Risk Factors
Preclinical validation challenges for novel degradation mechanisms, intense competition in the TPD space from better-funded companies, and dependency on parent company RaQualia Pharma post-acquisition.
Competitive Landscape
Competes with Arvinas, Kymera Therapeutics, and Nurix Therapeutics in targeted protein degradation, but differentiates through focus on pseudokinases, efficient chemistry platform, and strong Japanese academic network.